Rafferty Asset Management
CUE icon

Rafferty Asset Management’s Cue Biopharma CUE Stock Holding History

Rafferty Asset Management’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,235
Closed -$1.1M – 1239
2021
Q4 		$1.1M Buy
3,235
+1,935
+149% +$748K 0.01% 828
2021
Q3 		$568K Sell
1,300
-452
-26% -$158K ﹤0.01% 1017
2021
Q2 		$612K Sell
1,752
-227
-11% -$88K ﹤0.01% 1031
2021
Q1 		$724K Buy
1,979
+1,540
+351% +$634K ﹤0.01% 864
2020
Q4 		$165K Sell
439
-675
-61% -$270K ﹤0.01% 998
2020
Q3 		$503K Buy
1,114
+816
+274% +$470K 0.01% 696
2020
Q2 		$219K Buy
+298
New +$216K ﹤0.01% 907

Other funds holding CUE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rafferty Asset Management's CUE Position: Q1 2022 in Review

Rafferty Asset Management sold out of Cue Biopharma (CUE) in Q1 2022, closing a stake of 3,235 shares — an estimated $1.1M sold.

Rafferty Asset Management first reported a position in CUE in Q2 2020 and held it in 7 quarters. The position peaked at $1.1M in Q4 2021. 100 funds tracked by Wall St. Rank hold CUE as of Q1 2022.

  • Rafferty Asset Management reported no remaining Cue Biopharma position as of Q1 2022 after selling out during the quarter.
  • Rafferty Asset Management sold 3,235 Cue Biopharma shares in Q1 2022, an estimated $1.1M.
  • Rafferty Asset Management first reported a position in Cue Biopharma in Q2 2020 and held it in 7 quarters.
  • Rafferty Asset Management's Cue Biopharma position peaked at $1.1M in Q4 2021.
  • 100 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2022.

Based on Rafferty Asset Management's 13F filing for Q1 2022, filed 13 May 2022.